Assessment of the Initial Results of Pituitary Tumor Registry at a Tertiary Hospital of Iran: 2009–2022 Publisher



Mohseni S¹ ; Mirdamadi N¹ ; Mossavarali S² ; Mohajeritehrani MR¹ ; Pejman Sani M¹ Show Affiliations
Source: Journal of Diabetes and Metabolic Disorders Published:2024

Abstract

Objectives: The Pituitary Tumor Registry intends to provide a platform for clinical research and basic sciences, with an emphasis on disease outcomes. Methods: In this retrospective cohort study, all patient data, including demographics, vital signs, symptoms and signs, medical history, medications, past drug history, paraclinical data, treatment modalities, post-surgery follow-up, treatment responsiveness, and pathology reports, have been gathered from the electronic patient records of the Endocrinology and Metabolism Research Center affiliated with Tehran University of Medical Sciences. Results: A total of 200 patients with pituitary adenoma were identified. Acromegaly was the most prevalent adenoma, accounting for 35% (n = 70) of cases, followed by clinically nonfunctional pituitary adenoma (CNFPA) at 28.5% (n = 57), prolactinoma at 23% (n = 46), and Cushing disease at 13.5% (n = 27). All of the patients with Cushing disease had surgery, with trans-sphenoidal surgery accounting for 92.59%. Prolactinoma was mostly treated with medication (82.60% of cases). Post-operative complications were reported, including cerebrospinal fluid (CSF) leakage in CNFPA cases (24.13%, n = 7) and diabetes insipidus (DI) in acromegaly (13.46%, n = 7). Unfortunately, 5 patients died: two with acromegaly, two with CNFPA and one with Cushing disease. Conclusions: This registry permits a comprehensive management, long term follow up and treatment outcomes of patients with pituitary adenomas. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024.